TY - JOUR
T1 - LIN28B polymorphisms influence susceptibility to epithelial ovarian cancer
AU - Permuth-Wey, Jennifer
AU - Kim, Donghwa
AU - Tsai, Ya Yu
AU - Lin, Hui Yi
AU - Chen, Y. Ann
AU - Barnholtz-Sloan, Jill
AU - Birrer, Michael J.
AU - Bloom, Gregory
AU - Chanock, Stephen J.
AU - Chen, Zhihua
AU - Cramer, Daniel W.
AU - Cunningham, Julie M.
AU - Dagne, Getachew
AU - Ebbert-Syfrett, Judith
AU - Fenstermacher, David
AU - Fridley, Brooke L.
AU - Garcia-Closas, Montserrat
AU - Gayther, Simon A.
AU - Ge, William
AU - Gentry-Maharaj, Aleksandra
AU - Gonzalez-Bosquet, Jesus
AU - Goode, Ellen L.
AU - Iversen, Edwin
AU - Jim, Heather
AU - Kong, William
AU - McLaughlin, John
AU - Menon, Usha
AU - Monteiro, Alvaro N.A.
AU - Narod, Steven A.
AU - Pharoah, Paul D.P.
AU - Phelan, Catherine M.
AU - Qu, Xiaotao
AU - Ramus, Susan J.
AU - Risch, Harvey
AU - Schildkraut, Joellen M.
AU - Song, Honglin
AU - Stockwell, Heather
AU - Sutphen, Rebecca
AU - Terry, Kathryn L.
AU - Tyrer, Jonathan
AU - Vierkant, Robert A.
AU - Wentzensen, Nicolas
AU - Lancaster, Johnathan M.
AU - Cheng, Jin Q.
AU - Sellers, Thomas A.
PY - 2011/6/1
Y1 - 2011/6/1
N2 - Defective microRNA (miRNA) biogenesis contributes to the development and progression of epithelial ovarian cancer (EOC). In this study, we examined the hypothesis that single nucleotide polymorphisms (SNP) in miRNA biogenesis genes may influence EOC risk. In an initial investigation, 318 SNPs in 18 genes were evaluated among 1,815 EOC cases and 1,900 controls, followed up by a replicative joint meta-analysis of data from an additional 2,172 cases and 3,052 controls. Of 23 SNPs from 9 genes associated with risk (empirical P < 0.05) in the initial investigation, the meta-analysis replicated 6 SNPs from the DROSHA, FMR1, LIN28, and LIN28B genes, including rs12194974 (G>A), an SNP in a putative transcription factor binding site in the LIN28B promoter region (summary OR = 0.90, 95% CI: 0.82-0.98; P = 0.015) which has been recently implicated in age of menarche and other phenotypes. Consistent with reports that LIN28B overexpression in EOC contributes to tumorigenesis by repressing tumor suppressor let-7 expression, we provide data from luciferase reporter assays and quantitative RT-PCR to suggest that the inverse association among rs12194974 A allele carriers may be because of reduced LIN28B expression. Our findings suggest that variants in LIN28B and possibly other miRNA biogenesis genes may influence EOC susceptibility.
AB - Defective microRNA (miRNA) biogenesis contributes to the development and progression of epithelial ovarian cancer (EOC). In this study, we examined the hypothesis that single nucleotide polymorphisms (SNP) in miRNA biogenesis genes may influence EOC risk. In an initial investigation, 318 SNPs in 18 genes were evaluated among 1,815 EOC cases and 1,900 controls, followed up by a replicative joint meta-analysis of data from an additional 2,172 cases and 3,052 controls. Of 23 SNPs from 9 genes associated with risk (empirical P < 0.05) in the initial investigation, the meta-analysis replicated 6 SNPs from the DROSHA, FMR1, LIN28, and LIN28B genes, including rs12194974 (G>A), an SNP in a putative transcription factor binding site in the LIN28B promoter region (summary OR = 0.90, 95% CI: 0.82-0.98; P = 0.015) which has been recently implicated in age of menarche and other phenotypes. Consistent with reports that LIN28B overexpression in EOC contributes to tumorigenesis by repressing tumor suppressor let-7 expression, we provide data from luciferase reporter assays and quantitative RT-PCR to suggest that the inverse association among rs12194974 A allele carriers may be because of reduced LIN28B expression. Our findings suggest that variants in LIN28B and possibly other miRNA biogenesis genes may influence EOC susceptibility.
UR - http://www.scopus.com/inward/record.url?scp=79957905172&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79957905172&partnerID=8YFLogxK
U2 - 10.1158/0008-5472.CAN-10-4167
DO - 10.1158/0008-5472.CAN-10-4167
M3 - Article
C2 - 21482675
AN - SCOPUS:79957905172
SN - 0008-5472
VL - 71
SP - 3896
EP - 3903
JO - Cancer Research
JF - Cancer Research
IS - 11
ER -